Commercializing structural biology knowledge can save money and speed drug discovery – Phys.Org

June 2, 2017 by Grove Potter Artem Evdokimov, the CEO and chief science officer at HarkerBIO. Credit: Douglas Levere

HarkerBIO is a "shining star" in the growing biotech ecosystem taking shape on the Buffalo Niagara Medical Campus. The small structural biology company determines 3-D structures of proteins for drug and biotech companies.

That may sound straightforward even simple but the process is something right out of Star Trek. HarkerBIO uses sophisticated biochemical techniques, supercomputing power and laboratory expertise to decipher the giant, complex structures of proteins.

The company then uses that information to help pharmaceutical companies sleuth out sites where drug-like molecules may bind, eventually creating molecules for new medicines. Biotech companies, meanwhile, use the structural data to improve enzyme catalysts that hasten difficult chemical transformations.

HarkerBIO was formed in 2015 by Hauptman-Woodward Medical Research Institute, which is home to the Department of Structural Biology at the Jacobs School of Medicine and Biomedical Sciences at UB, to commercialize Hauptman-Woodward's expertise in X-ray crystallography.

It now has 14 employees, participates in the START-UP NY economic development program and has a partnership with Albany Molecular Research Inc., a contract research and manufacturing organization with a lab on the medical campus.

Drug discovery

"When you're discovering a drug, you have a lot of small molecules to choose from. You have quintillions of options more than all the stars in the universe," said Artem Evdokimov, PhD, the CEO and chief science officer at HarkerBIO. "But only a few are good. The rest are not useful."

One way to find molecules that attach to proteins is to simply try them all. Today companies can experimentally test several million different molecules to find out if any work.

A much more affordable and flexible method is to screen them in a virtual worldinside a computer. To do this, scientists probe a three-dimensional structure of the protein (with tens of thousands of atoms or more) with billions of virtual chemicals inside a computer simulation. When some of the virtual compounds "stick" to the protein structure, they can be made by chemists in a laboratory and then tested to see if they actually bind. Thus, the number of molecules that need to be made and tested is reduced from millions to hundreds or less.

"Ultimately, molecules will get made by a chemist and then tested," Evdokimov said. "Drug design is a cyclic process. You find something that sort of works, and you study it and you change it, and then you make it better."

Commercializing expertise

In the small but competitive world of structural biology, HarkerBIO has an advantage in its specialization. HarkerBIO's scientists consult with prospective customers to discuss their needs and goals in-depth. Sometimes if the project is too challenging, HarkerBIO will help the client define the goals to be more realistic.

"Structural biology is unique in one way," said James Biltekoff, executive chairman of the company. "There is a huge economic benefit to our clients in getting to 'no.' If an idea is a bust, let's find out before they spend $10 or $20 million. Structure is hard data that can tell you whether or not something is going to work."

The long-range goal of the company is to maintain the high-level focus on structure and enhance its role as a "knowledge partner," Biltekoff said.

"And we want to add on a more propriety research function, focused on both the drug discovery process, and on the techniques that we use in structural biology," he said.

That includes devoting staff time to discovery. "My vision for the company is that all the senior people should eventually be able to use 15 percent of their time on intellectual pursuits," he said.

Capturing proteins

Scientists at HarkerBIO must first get a sample of the target protein. This is accomplished by making cultured cells (bacteria, yeast, insect or human cells) into little factories that produce the protein of interest. Then the protein is purified from cellular extracts and crystallized. Typical protein crystals are less than a tenth of a millimeter long, invisible to the naked eye. These tiny protein crystals must be fished out of their growth solutionby hand, under a microscopeand quickly frozen in liquid nitrogen.

"Trying to crystalize a protein is very, very hard. Proteins have irregular and floppy shapes, like a teddy bear" Evdokimov said. "Imagine piling hundreds of plushy bears in a heapyou just get an irregular pile, not regular arrays like crystalsand that's what has to happen with protein molecules in order for us to study them."

Once a protein is successfully crystalized, it is sent to a government-owned synchrotron facility: a loop three miles in diameter where electrons are blasted around in a vacuum to create a super bright X-ray beam that is focused on the crystal. X-rays are diffracted by the crystal forming a pattern of spots that can be mathematically interpreted into the exact atomic structure of the protein molecule.

Cost of structural work varies from thousands to hundreds of thousands of dollars, depending on the complexity of the proteins. There are other companies that do similar work, but Evdokimov said HarkerBIO has a very high success rate that companies desire.

Shining star

"HarkerBIO is one of our bright shining stars," said Kim Grant, business development executive at UB's New York State Center of Excellence in Bioinformatics and Life Sciences. "They cut cost out of drug development research."

Laura Sailor, HarkerBIO's corporate development officer, said the company is making a name for itself.

"We are getting recognized on both coasts, by large pharma, biotechs and virtuals," she said. "Adding structural biology in the lead discovery program early on will accelerate your timelines and give you less failures."

"Our edge is that we understand structure and thus function. It is the loss or gain of function that can result in disease," Sailor added. "We sell the insight, structural insight for designing drugs or mechanisms for action."

"We only do structure. We are the structure people."

Explore further: Iodine ensures successful solution of biomolecule structures

An international team including researchers from MIPT has shown that iodide phasinga long-established technique in structural biologyis universally applicable to membrane protein structure determination. Knowledge of ...

A new set of machine learning algorithms developed by U of T researchers that can generate 3D structures of tiny protein molecules may revolutionize the development of drug therapies for a range of diseases, from Alzheimer's ...

Crew members aboard the International Space Station will begin conducting research this week to improve the way we grow crystals on Earth. The information gained from the experiments could speed up the process for drug development, ...

The first three-dimensional (3-D) structure of a human protein complex within intact mammalian cells has been obtained directly by A*STAR scientists. It could provide new opportunities in structural biology, in developing ...

A team of scientists from MIPT, Research Center Jlich (Germany), and Institut de Biologie Structurale (France) has developed a new approach to membrane protein crystallization. For the first time, the scientists have showed ...

Annette Rompel and her team of the Department of Biophysical Chemistry at the University of Vienna are investigating so-called polyoxometalates. These compounds exhibit a great diversity and offer the scientists a wide range ...

As the United Nations Oceans Conference convenes in New York, a new paper calls on marine scientists to focus on social issues such as human rights violations in the seafood industry.

Scientists are now confident animal life on solid ground started with a few short bursts of marine creatures making the leap from the oceans.

Scientists have watched a cell's genetic machinery in the first stages of 'reading' genes, giving a potential way to stop the process in bacteria.

Once we start coloring our hair, we may be surprised to learn that we begin to have a problem in common with plant biologists: finding the right dye for our roots. In the case of the biologists, just the right chemical is ...

Passing skills down through the generations, previously thought to be unique to humanity, has been discovered in chimpanzees.

The flightless cormorant is one of a diverse array of animals that live on the Galapagos Islands, which piqued Charles Darwin's scientific curiosity in the 1830s. He hypothesized that altered evolutionary pressures may have ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

See the rest here:
Commercializing structural biology knowledge can save money and speed drug discovery - Phys.Org